Athersys to Present at Jefferies 2019 Healthcare Conference
June 04 2019 - 6:00AM
Athersys, Inc. (NASDAQ: ATHX) announced today that Dr. Gil Van
Bokkelen, Chairman and CEO, will present at the Jefferies 2019
Healthcare Conference taking place June 4-7, 2019 in New York
City. Dr. Van Bokkelen’s presentation will take place at 11
AM Eastern Time on June 7, 2019 and will focus on the Company’s
mission and the clinical development of its MultiStem® cell
therapy. The talk will also summarize the recent positive
data from its exploratory Phase 1/2 clinical study evaluating
MultiStem cell therapy for the treatment acute respiratory distress
syndrome (ARDS), and the ARDS clinical program has received Fast
Track designation from the U.S. Food and Drug Administration for
the next phase of development.
This event draws approximately 400 participating companies and
over 2,600 attendees and features an extensive range of public and
private healthcare companies across the Biopharmaceuticals, Life
Sciences, Healthcare Services, Healthcare IT and Medical Technology
sectors. This global gathering of leading executives, institutional
investors, private equity investors and venture capitalists will
address near- and long-term investment opportunities and discuss
the mechanisms driving healthcare in the U.S. and
internationally.
About MultiStem
MultiStem cell therapy is a patented regenerative medicine
product in clinical development that has shown the ability to
promote tissue repair and healing in a variety of ways, such as
through the production of therapeutic factors produced in response
to signals of inflammation and tissue damage. MultiStem therapy’s
potential for multidimensional therapeutic impact distinguishes it
from traditional biopharmaceutical therapies focused on a single
mechanism of benefit. The therapy represents a unique
"off-the-shelf" stem cell product that can be manufactured in a
scalable manner, may be stored for years in frozen form, and is
administered without tissue matching or the need for immune
suppression. Based upon its efficacy profile, its novel mechanisms
of action, and a favorable and consistent safety profile
demonstrated in clinical studies, MultiStem therapy could provide a
meaningful benefit to patients, including those suffering from
serious diseases and conditions with unmet medical need.
About Athersys
Athersys is an international biotechnology company engaged in
the development of therapeutic products designed to extend and
enhance the quality of human life. The Company is developing its
MultiStem® cell therapy product, a patented, adult-derived
“off-the-shelf” stem cell product, initially for disease
indications in the neurological, cardiovascular, and inflammatory
and immune disease areas, and has several ongoing clinical trials
evaluating this potential regenerative medicine product. Athersys
has forged strategic partnerships and a broad network of
collaborations to further advance MultiStem cell therapy toward
commercialization. More information is available at
www.athersys.com.
William (B.J.) LehmannPresident and Chief Operating OfficerTel:
(216) 431-9900bjlehmann@athersys.com
Karen HunadyDirector of Corporate Communications &
Investor RelationsTel: (216) 431-9900khunady@athersys.com
David SchullRusso Partners, LLCTel: (212) 845-4271 or (858)
717-2310David.schull@russopartnersllc.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Sep 2023 to Sep 2024